CClinicalTrials.gg
CompletedNCT05511155Updated Oct 4, 2022

Oxygen Therapy for Headache

An observational study in Primary Headache Disorder, sponsored by Aksaray University Training and Research Hospital. Completed at 1 site in Turkey. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2022-10-04.

Sponsored by Aksaray University Training and Research Hospital · Observational

Study type
Observational
Model
Case-crossover
Time perspective
Prospective
Enrollment
132
Ages
18 Years to 55 Years
Sex
All
01

Study summary

Headache is one of the common causes of emergency department admissions and constitutes approximately 2%. Although the exact mechanism is not clear, It is known that high-flow oxygen therapy is effective in headache treatment. There are limited studies related to the use of oxygen therapy in headaches and its derivatives in the literature. In this study, the investigators aimed to compare the high and medium flow oxygen therapies with placebo in primary headache disorders.

Read the detailed description

Four different treatment methods were determined; 1) high-flow oxygen (15lt/min oxygen), 2) medium-flow oxygen (8lt/min oxygen), 3) high-flow room air as placebo (15 lt/min room air), 4) medium-flow room air as placebo (8 lt/min room air). All four treatment methods will be applied to all patients included in the study. One of the four treatments will be randomly applied at each separate ED admission with a gap of 1 week or more in between. This randomization will be performed by a computer at the time of admission. A study nurse will administer the patient's therapy according to the computer's current decision for 15 minutes. Patients and treating physicians will be blinded to the selected therapy. After 15 minutes of the end of treatment (at the 30th minute of the start of treatment), the treating physician will ask patients if they need rescue analgesia and analgesia will be administered if necessary. Additional analgesia is at the discretion of the treating physician. Patient data, including demographics, medical history, and findings of a physical examination performed before and after therapy will be recorded by the treating physician.

02

Conditions studied

  • Primary Headache Disorder

Keywords

  • oxygen therapy
  • migraine
  • emergency department
  • cluster type headache
03

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

all patients had one to six headache attacks per month which were started before 50 years old and were present for more than one year.

Inclusion criteria

  • age 18-55 years
  • frequent attacks of primary headache disorders according to International Headache Society (IHS) criteria

Exclusion criteria

Exclusion Criteria:

  • secondary headache disorders
  • oxygen-dependent chronic illnesses such as chronic obstructive pulmonary disease
  • a history of cerebrovascular disease
  • pregnancy
  • active smokers or living with a smoker.
04

Study design

Observational model
Case-crossover
Time perspective
Prospective
Enrollment
132 participants (actual)
Patient registry
No

Groups and cohorts

  • O-15

    15 lt/min oxygen

    Other: Oxygen therapy

  • O-8

    8 lt/min oxygen

    Other: Oxygen therapy

  • A-15

    15 lt/min room air

    Other: Oxygen therapy

  • A-8

    8 lt/min room air

    Other: Oxygen therapy

Interventions

  • OtherOxygen therapy

    Oxygen therapy will be given for 15 minutes with a non-rebreathing mask.

05

What researchers measure

Primary outcomes

  1. visual analog scale score

    primary endpoint is the relative reduction in visual analog scale (a psychometric response scale) score in the placebo versus oxygen group to determine whether there was a difference between the high-flow and mid-flow therapies. visual analog scale scaled from 0-100 points with 0 meaning "no pain" and 100 points meaning "worst possible pain".

    Time frame: 0-60 minutes

Secondary outcomes

  1. rescue analgesia

    rescue analgesia (yes/no)

    Time frame: 30 th minutes

  2. length of stay

    length of stay in the emergency department (time in minutes)

    Time frame: 0-300 minutes

  3. duration of a pain

    duration of a pain attack (time in minutes)

    Time frame: 0-300 minutes

  4. readmission

    readmission to the emergency department within 7 days (yes/no)

    Time frame: 0-7 days

06

Study locations

1 site
  • Aksaray University Aksaray Training and Research Hospital
    Aksaray, 68200, Turkey
07

References and documents

Publications

  • Friedman BW, Grosberg BM. Diagnosis and management of the primary headache disorders in the emergency department setting. Emerg Med Clin North Am. 2009 Feb;27(1):71-87, viii. doi: 10.1016/j.emc.2008.09.005. PubMed 19218020 ↗
  • Roberto G, Raschi E, Piccinni C, Conti V, Vignatelli L, D'Alessandro R, De Ponti F, Poluzzi E. Adverse cardiovascular events associated with triptans and ergotamines for treatment of migraine: systematic review of observational studies. Cephalalgia. 2015 Feb;35(2):118-31. doi: 10.1177/0333102414550416. Epub 2014 Sep 22. PubMed 25246519 ↗
  • Mo H, Chung SJ, Rozen TD, Cho SJ. Oxygen Therapy in Cluster Headache, Migraine, and Other Headache Disorders. J Clin Neurol. 2022 May;18(3):271-279. doi: 10.3988/jcn.2022.18.3.271. PubMed 35589316 ↗
  • Petersen AS, Barloese MC, Lund NL, Jensen RH. Oxygen therapy for cluster headache. A mask comparison trial. A single-blinded, placebo-controlled, crossover study. Cephalalgia. 2017 Mar;37(3):214-224. doi: 10.1177/0333102416637817. Epub 2016 Jul 11. PubMed 27013239 ↗

Individual participant data

Plan to share: No

08

Registry details

Key details

Study ID
NCT05511155
Lead sponsor
Aksaray University Training and Research Hospital
Responsible party
ilker kacer (Medical Doctor, Aksaray University Training and Research Hospital) — Principal investigator
First posted
Aug 22, 2022
Start date
Jul 1, 2022
Primary completion
Aug 31, 2022
Completion
Sep 30, 2022
Last update
Oct 4, 2022

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion